How does valsartan work to block angiotensin II receptors and cause vasodilation?

How Valsartan Works

Valsartan blocks angiotensin II from binding to AT1 receptors on blood vessels, preventing vasoconstriction and aldosterone release, which leads to vasodilation and blood pressure reduction. 1

Mechanism of Action

Angiotensin II is the body's principal pressor (blood pressure-raising) agent, causing:

• Vasoconstriction (narrowing of blood vessels)
• Aldosterone secretion (sodium and water retention)
• Cardiac stimulation
• Renal sodium reabsorption

Valsartan selectively blocks the AT1 receptor where angiotensin II normally binds, particularly in vascular smooth muscle and the adrenal gland. This blockade prevents angiotensin II from exerting its vasoconstrictor and aldosterone-secreting effects 1.

Key Pharmacologic Features:

• Receptor specificity: Valsartan has approximately 20,000-fold greater affinity for AT1 receptors compared to AT2 receptors 1
• Competitive antagonism: When given simultaneously with angiotensin II, valsartan causes a rightward shift in the dose-response curve 2
• Partial insurmountability: Valsartan also demonstrates tight binding characteristics with relatively slow dissociation (half-life ~17 minutes), contributing to sustained blood pressure control 2

Important Distinction from ACE Inhibitors:

Unlike ACE inhibitors (which block angiotensin II formation), valsartan works downstream by blocking the receptor itself. Valsartan does not inhibit ACE (kininase II), so it does not affect bradykinin degradation 1. This explains why valsartan does not cause the dry cough commonly seen with ACE inhibitors—a significant clinical advantage.

Physiologic Effects

Blood Pressure Lowering:

• An 80 mg oral dose inhibits the pressor effect of angiotensin II by approximately 80% at peak, with about 30% inhibition persisting for 24 hours 1
• Despite increased plasma renin activity (2-3 fold rise) and consequent angiotensin II levels due to loss of negative feedback, valsartan's receptor blockade overcomes these compensatory increases 1

Additional Vascular Effects:

Beyond simple receptor blockade, valsartan demonstrates anti-inflammatory effects on blood vessels. It reduces expression of monocyte chemoattractant protein-1 (MCP-1) and inflammatory cytokines (TNF-α, IL-6, IL-1β), decreasing leukocyte and macrophage infiltration in injured arteries 3. This may contribute to regression of atherosclerosis independent of blood pressure reduction 4.

Metabolic Neutrality:

Valsartan has no clinically significant effects on total cholesterol, triglycerides, fasting glucose, or uric acid 1—making it metabolically neutral.

Clinical Implications

The net result of AT1 receptor blockade is:

1. Vasodilation (blood vessels relax and widen)
2. Reduced aldosterone (less sodium/water retention)
3. Decreased cardiac workload
4. Maintained renal function (no significant effects on GFR, creatinine clearance, or renal plasma flow) 1

Guideline Context:

Current ESC guidelines (2024) recommend angiotensin receptor blockers like valsartan as first-line therapy for hypertension, typically in combination with other agents 5. The combination approach targets multiple pathophysiological pathways and improves adherence through single-pill formulations.

Common pitfall: Food decreases valsartan absorption by approximately 40% (AUC) and peak concentration by 50% 1, though it can be administered with or without food as the clinical effect remains adequate.